Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This is an open label, single-arm, phase IB treatment study to determine the safety of
administering anti-PD1 monoclonal antibodies with AV-MEL-1 and to get some suggestion of
efficacy, in patients with measurable metastatic melanoma. These will be patients who have
either never received treatment for metastatic melanoma or were previously treated with
enzymatic inhibitors of the BRAF/MEK pathway because of BRAF600E/K mutations, and are about
to initiate anti-PD1 monotherapy. The intent is to treat 14 to 20 patients with the
combination of anti-PD-1 and AV-MEL-1.